Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 7;11(9):ofae497. doi: 10.1093/ofid/ofae497

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Timeline of trials testing nirmatrelvir/ritonavir and/or molnupiravir in patients with coronavirus disease 2019. Red indicates negative results for hospitalization and death, green indicates positive results for hospitalization and death, yellow indicates softer outcomes (eg, viral clearance), and gray indicates no published results. The width of the bar represents the time between the start and end of enrollment. The blue line in the background indicates the percentage of the population with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies (https://COVID.cdc.gov/COVID-data-tracker/#nationwide-blood-donor-seroprevalence). Abbreviations: RECOVERY, randomised evaluation of covid-19 therapy; EPIC-SR, evaluation of protease inhibition for covid-19 in standard-risk patients; EPIC-HR, evaluation of protease inhibition for covid-19 in high-risk patients.